Skip to main content
HINOVA PHARMACEUTICALS INC. logo

HINOVA PHARMACEUTICALS INC. — Investor Relations & Filings

Ticker · 688302 ISIN · CNE1000059F5 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2026-05-15 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688302

About HINOVA PHARMACEUTICALS INC.

https://www.hinovapharma.com/

Hinova Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of cancers and metabolic diseases. The company leverages its core technology platforms, including targeted protein degradation (PROTAC) and deuterium-based drug discovery, to develop a diverse pipeline of small molecule therapeutics. Its lead candidate, HC-1119 (deuterenzalutamide), is a next-generation androgen receptor antagonist currently in late-stage clinical development for metastatic castration-resistant prostate cancer. Other key programs include HP518, an orally bioavailable PROTAC degrader targeting the androgen receptor, and HP501, a selective URAT1 inhibitor designed for the treatment of hyperuricemia and gout. Hinova aims to address significant unmet medical needs through the development of high-quality, differentiated therapies for global markets.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于海创药业股份有限公司2025年度持续督导工作现场检查报告
Regulatory Filings Classification · 85% confidence The document is a continuous supervision on-site inspection report prepared by the sponsor (CITIC Securities) under Shanghai Stock Exchange self-regulatory guidelines. It does not present full audited financial statements (so not an Annual Report or Interim Report), nor is it a voting result, governance code, earnings release, or capital market announcement. It is a specialized regulatory compliance report, which best fits the fallback “Regulatory Filings” category (RNS).
2026-05-15 Chinese
中信证券股份有限公司关于海创药业股份有限公司2025年度持续督导跟踪报告
Regulatory Filings Classification · 85% confidence The document is a sponsor’s continuous supervision 2025 annual follow-up report for HaiChuang Pharmaceutical’s IPO on the Sci-Tech Innovation Board, prepared by CITIC Securities under regulatory requirements. It is not the company’s annual or interim report, audit report, earnings release, or other specific category. It serves as a compliance/regulatory filing documenting the sponsor’s ongoing monitoring activities, risk findings, and financial analysis. Therefore, it falls under the fallback category “Regulatory Filings” (RNS).
2026-05-15 Chinese
北京通商（成都）律师事务所关于海创药业股份有限公司2025年年度股东会的法律意见书
AGM Information Classification · 76% confidence The document is a legal opinion letter (“法律意见书”) prepared by outside counsel regarding the convening, procedures, attendees, voting process, and results of the company’s 2025 Annual General Meeting. It is not an actual financial report or earnings release; rather, it forms part of the AGM materials submitted and published in connection with the annual shareholder meeting. Therefore, it best fits the AGM Information category.
2026-05-15 Chinese
2025年年度股东会会议资料
Regulatory Filings
2026-05-07 Chinese
2025年度募集资金存放、管理与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2025年度募集资金存放、管理与实际使用情况的专项报告" which translates to "2025 Annual Special Report on the Deposit, Management and Actual Use of Raised Funds." It details the company's fundraising amount, usage, management, and compliance with regulatory rules related to raised funds from an IPO. It includes detailed tables on funds raised, usage, cash management, project investment, and changes to investment projects. It also contains auditor and sponsor opinions on the compliance and proper use of the raised funds. The document references regulatory rules specific to fundraising and is a specialized report on fundraising usage and management for the year 2025. This matches the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document is not a full annual report, audit report, or earnings release, but a specialized fundraising usage report. The length and detail confirm it is the report itself, not just an announcement. Therefore, the correct classification is CAP with high confidence.
2026-04-24 Chinese
2025年度会计师事务所履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is titled '2025年度会计师事务所履职情况评估报告' which translates to '2025 Annual Evaluation Report on the Performance of the Accounting Firm'. It details the audit firm's qualifications, independence, quality management, and audit work related to the company's 2025 annual financial report and internal controls. The document is an evaluation of the auditor's performance rather than the audit report itself or the full annual report. It does not contain financial statements or substantive financial data but rather an assessment of the audit firm's work and compliance with regulations. The document length is 3977 characters, which is relatively short and consistent with an evaluation or audit report information document. Therefore, this fits best under the category 'Audit Report / Information (AR)', which includes standalone audit reports and related information excluding full annual reports.
2026-04-24 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.